Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | G6PD | P11413 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | DAB2IP | Q5VWQ8 | 1/20 | 1.00 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.84 |
| ▸ | SHBG | P04278 | 2/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13123058 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL15491309 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL225053 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL225052 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL12027476 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL6010005 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL4206793 | 0.91 | CYP19A1 (1.00) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL12820981 | 0.91 | CYP19A1 (1.00) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL12088879 | 0.91 | CYP19A1 (1.00) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL3868013 | 0.91 | CYP19A1 (1.00) | ESR1ESR2MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096781-A1 | METHODS AND COMPOSITIONS FOR PROVIDING CUSTOMIZED SKIN REGIMENS | VIBRANT HOLDINGS, LLC (US) | 2025-05-08 | — | — | WO | claimed |
| WO-2024259428-A2 | ESTROGENIC COMPOUNDS AND FORMULATIONS FOR GESTATION-RELATED COMPLICATIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-12-19 | — | — | WO | claimed |
| EP-4288539-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE ASSOCIATED WITH DUX4 OVEREXPRESSION | Research Institute at Nationwide Children's Hospital (US) | 2023-12-13 | — | — | EP | claimed |
| WO-2022169922-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE ASSOCIATED WITH DUX4 OVEREXPRESSION | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (US) | 2022-08-11 | — | — | WO | claimed |
| EP-4021369-A1 | MEDICAL DEVICES FOR CONTINUOUS DELIVERY OF THERAPEUTIC AGENTS | Forman, Mervyn B. (US) | 2022-07-06 | — | — | EP | claimed |
| WO-2022082183-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF INFLAMMATORY AND METABOLIC DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-21 | — | — | WO | claimed |
| EP-4735592-A2 | THERAPEUTIC METHOD FOR MODULATING COMPARTMENTED CYCLIC ADENOSINE MONOPHOSPHATE IN REACTIVE ASTROCYTES | The Board of Trustees of the Leland Stanford Junior University (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4729935-A2 | AUTOMATED CLINICAL DIAGNOSTIC SYSTEM AND METHOD | F. Hoffmann-La Roche AG (CH) | 2026-04-22 | — | — | EP | disclosed |
| US-12600700-B2 | Imidazolium reagent for mass spectrometry | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4267951-B1 | AUTOMATED CLINICAL DIAGNOSTIC SYSTEM AND METHOD | HOFFMANN LA ROCHE (CH) | 2026-03-25 | — | — | EP | disclosed |
| EP-4153565-B1 | BENZYLPYRIDINIUM REAGENT FOR MASS SPECTROMETRY | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| EP-3577466-B1 | REAGENT FOR MASS SPECTROMETRY | ROCHE DIAGNOSTICS GMBH (DE) | 2026-01-07 | — | — | EP | disclosed |
| US-20250347654-A1 | DETECTION OF AN ANALYTE OF INTEREST BY A CHIP BASED NANOESI DETECTION SYSTEM | ROCHE DIAGNOSTICS OPERATIONS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-11442046-B2 | Reagent for mass spectrometry | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| WO-2022169922-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE ASSOCIATED WITH DUX4 OVEREXPRESSION | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (US) | 2022-08-11 | — | — | WO | disclosed |
| US-20220211612-A1 | GEL BASE COMPOSITION FOR COMPOUNDING INTO A MUCOADHESIVE DELIVERY SYSTEM | Medisca Pharmaceutique Inc. (CA) | 2022-07-07 | — | — | US | disclosed |
| EP-4021369-A1 | MEDICAL DEVICES FOR CONTINUOUS DELIVERY OF THERAPEUTIC AGENTS | Forman, Mervyn B. (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20220178951-A1 | METHOD FOR QUANTITATIVE MEASUREMENT OF CATECHOL ESTROGEN BOUND PROTEIN IN BLOOD SAMPLE | NATIONAL CHENG KUNG UNIVERSITY (TW) | 2022-06-09 | — | — | US | disclosed |
| US-11337955-B2 | Compositions and methods to regulate hormonal cascades in stress disorders | BIOMMUNITY, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| WO-2022082183-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF INFLAMMATORY AND METABOLIC DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600700-B2 | Imidazolium reagent for mass spectrometry | SRMS, PTMS, F2 | ESR1 531/4885ESR2 614/4885MEN1 1719/4885 |
| US-11337955-B2 | Compositions and methods to regulate hormonal cascades in stress disorders | PRLHR, FKBP1A, CRH | ESR1 30/4885ESR2 26/4885MEN1 2210/4885 |
| US-11442046-B2 | Reagent for mass spectrometry | PTMS, MAN2B2, CA14 | ESR1 4421/4885ESR2 4637/4885MEN1 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.